Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06450171 · ClinicalTrials.gov registry record · NA
Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Population: The INFORM Study
A NA study of Cancer Predisposition Syndrome and Predisposition, Genetic, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT06450171: Recruiting NA study of Cancer Predisposition Syndrome and Predisposition, Genetic, sponsored by Dana-Farber Cancer Institute.
NCT06450171 is a NA study of Cancer Predisposition Syndrome and Predisposition, Genetic that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 1,000 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06450171, a NA study of Cancer Predisposition Syndrome and Predisposition, Genetic, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to evaluate the possible benefits and harms of screening with an investigational blood test designed to detect many types of cancer early. The name of the screening blood test being studied is: -GRAIL Galleri test
Primary Outcome
Descriptive statistics will be used to summarize the number and types of cancers diagnosed by GRAIL Galleri MCED testing.
Conditions Studied
Interventions
- OTHER GRAIL Galleri Test
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2024-09-27 |
| Est. Completion | 2028-01-31 |
| Phase | NA |
What NCT06450171 shows while recruiting
NCT06450171 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower).
The record links to 2 conditions, with Cancer Predisposition Syndrome appearing as the primary indexed condition, and to 1 intervention - of which GRAIL Galleri Test is the first listed.
NCT06450171 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06450171 about?
NCT06450171 is a clinical study titled "Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Population: The INFORM Study". The purpose of this research study is to evaluate the possible benefits and harms of screening with an investigational blood test designed to detect many types of cancer early. The name of the screening blood test being studied is: -GRAIL Galleri test
What is the current status of trial NCT06450171?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2024-09-27. Estimated completion is 2028-01-31.
What conditions does trial NCT06450171 study?
This clinical trial studies the following conditions: Cancer Predisposition Syndrome, Predisposition, Genetic.
What interventions are being tested in trial NCT06450171?
The interventions under investigation include: GRAIL Galleri Test (OTHER).
Who is sponsoring clinical trial NCT06450171?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06450171 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer Predisposition Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06450171's enrollment target sits among peer trials
1,000 107th of 2000 higher than 1,880 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI